We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
51
Harrow
HROW
$1.4B
$1.67M 0.05%
125,967
-1,372,617
-92% -$14.6M
AMGN icon
52
Amgen
AMGN
$234B
– –
-58,200
Closed -$16.8M
CMPX icon
53
Compass Therapeutics
CMPX
$432M
– –
-317,761
Closed -$496K
DNLI icon
54
Denali Therapeutics
DNLI
$3.84B
– –
-461,769
Closed -$9.91M
DYN icon
55
Dyne Therapeutics
DYN
$4.68B
– –
-755,811
Closed -$10.1M
HLVX
56
DELISTED
HilleVax
HLVX
– –
-203,407
Closed -$3.26M
IMCR icon
57
Immunocore
IMCR
$1.89B
– –
-611,365
Closed -$41.8M
LNTH icon
58
Lantheus
LNTH
$6.58B
– –
-495,100
Closed -$30.7M
MRUS
59
DELISTED
Merus
MRUS
– –
-370,679
Closed -$10.2M
RAPT
60
DELISTED
RAPT Therapeutics
RAPT
– –
-48,663
Closed -$9.67M
TERN
61
DELISTED
Terns Pharmaceuticals
TERN
– –
-2,318,050
Closed -$15M
THRD
62
DELISTED
Third Harmonic Bio
THRD
– –
-1,316,018
Closed -$14.4M
VRDN icon
63
Viridian Therapeutics
VRDN
$2.61B
– –
-323,102
Closed -$7.04M
1 2
3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.